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Abstract
Background
Age patterns in asymptomatic and symptomatic infection with Leishmania donovani, the
causative agent of visceral leishmaniasis (VL) in the Indian subcontinent (ISC), are currently
poorly understood. Age-stratified serology and infection incidence have been used to
assess transmission levels of other diseases, which suggests that they may also be of use
for monitoring and targeting control programmes to achieve elimination of VL and should be
included in VL transmission dynamic models. We therefore analysed available age-stratified
data on both disease incidence and prevalence of immune markers with the aim of collating
the currently available data, estimating rates of infection, and informing modelling and future
data collection.
Methodology/Principal findings
A systematic literature search yielded 13 infection prevalence and 7 VL incidence studies
meeting the inclusion criteria. Statistical tests were performed to identify trends by age, and
according to diagnostic cut-off. Simple reversible catalytic models with age-independent
and age-dependent infection rates were fitted to the prevalence data to estimate infection
and reversion rates, and to test different hypotheses about the origin of variation in these
rates. Most of the studies showed an increase in infection prevalence with age: from≲10%
seroprevalence (<20% Leishmanin skin test (LST) positivity) for 0-10-year-olds to >10%
seroprevalence (>20% LST-positivity) for 30-40-year-olds, but overall prevalence varied
considerably between studies. VL incidence was lower amongst 0-5-year-olds than older
age groups in most studies; most showing a peak in incidence between ages 5 and 20. The
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age-independent catalytic model provided the best overall fit to the infection prevalence
data, but the estimated rates for the less parsimonious age-dependent model were much
closer to estimates from longitudinal studies, suggesting that infection rates may increase
with age.
Conclusions/Significance
Age patterns in asymptomatic infection prevalence and VL incidence in the ISC vary consid-
erably with geographical location and time period. The increase in infection prevalence with
age and peaked age-VL-incidence distribution may be due to lower exposure to infectious
sandfly bites in young children, but also suggest that acquired immunity to the parasite
increases with age. However, poor standardisation of serological tests makes it difficult to
compare data from different studies and draw firm conclusions about drivers of variation in
observed age patterns.
Author summary
As the elimination target for visceral leishmaniasis (VL) in the Indian subcontinent (<1
case/10,000 people/year) is approached, there is a growing need for surveillance tools with
which to monitor transmission to ensure the target is sustained, especially given the large
proportion of infections which are asymptomatic (~75–95%). One potential approach to
estimate underlying transmission patterns may be to track age patterns in infection or
cumulative exposure using diagnostic tests. However, current understanding of age pat-
terns in asymptomatic infection and clinical VL is poor, in particular regarding possible
age-dependence of infection rates. Our systematic review and pooled-analysis of age-strat-
ified data on infection prevalence and disease incidence suggests that available diagnostics,
as currently implemented, fail to meet the requirements for a reliable tool for assessing
transmission, due to inconsistent standardisation and highly variable age-prevalence pat-
terns across different settings. It also finds weak evidence for infection rates increasing
with age, though further longitudinal studies are needed to test this hypothesis and to
assess whether properly standardised diagnostic tests could be used to monitor ongoing
transmission.
Introduction
The Indian subcontinent (ISC) appears to be on course to reach the target of elimination of
visceral leishmaniasis (VL) as a public health problem (less than 1 case/10,000 people/year at
sub-district level) in most sub-districts by 2020 [1–3]. Once this goal has been achieved, sur-
veillance methods that require fewer resources than active case detection will be required to
monitor transmission and provide early warning of possible resurgence [4]. One proposed
method is monitoring age patterns in infection prevalence by serology or other diagnostic tests
[4]. This approach has been used successfully for other vector-borne diseases, such as malaria
[5–7], dengue [8] and Chagas disease [9–11], However, it is unclear whether it would be effec-
tive for VL surveillance with currently available diagnostics. Additionally, mathematical mod-
els of VL transmission dynamics are useful tools for understanding disease patterns and
designing cost-effective control strategies [2,12–15], and it is unknown whether age-structure
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is required within such models. The existence of evidence for age-related risk of infection and
the viability of age-stratified serology as a post-elimination surveillance tool are the key issues
we address in this review.
Almost 147 million people are at risk from VL in the ISC, caused by Leishmania donovani
[16]. Elimination as a public health problem is considered to be possible based on the beliefs
that indoor residual spraying (IRS) of insecticide is effective and that transmission is exclu-
sively anthroponotic, combined with the availability of effective diagnostics and therapeutics
to curtail the infectious period [17]. As of 2016, significant progress had been made towards
reaching the elimination target, with an 82% decrease in new cases since 2011 and the target
being reached in a number of previously endemic sub-districts [18]. In 2017, sub-district level
incidence in India ranged between 0 and 12 cases/10,000 people/year and only 72 out of 633
endemic sub-districts were above the elimination target [19]; all endemic sub-districts in Ban-
gladesh and districts in Nepal reported incidence <1 case/10,000 people/year [1,20].
Current elimination strategies in the ISC are based on early case detection and treatment,
including education of at-risk populations, and methods to reduce abundance of the Phleboto-
mus argentipes sandfly vector such as IRS. Research has also identified the need to strengthen
existing VL epidemiological surveillance programmes in order to aid disease detection and
elimination [21]. However, only three large longitudinal VL studies have been carried out in
order to assess infection and disease progression. These sources of data are the KALANET bed
net trial in India and Nepal (2006–2009) [22], the Tropical Medicine Research Council
(TMRC) study in India (2007-) [23], and the CDC- and ICDDR,B-funded study conducted by
Bern and co-workers in Bangladesh (2002–2004) [24,25]. The scarcity of detailed, contempo-
rary longitudinal data means that the progression, epidemiology, and transmission dynamics
of the disease are still poorly understood [4].
The majority of infected individuals are asymptomatic, and never develop clinical symp-
toms, and estimates of the ratio of incident asymptomatic infection to incident VL vary from
4:1 [24] to 17:1 [26,27]. This variation may be related to differences in transmission intensity
and levels of immunity in different regions and time periods (the ratio appears to decrease as
VL incidence increases [27]), and/or differences in the definition of asymptomatic infection
between studies (i.e. the diagnostic test(s) and cut-offs used), as there is no agreed definition or
gold-standard test for asymptomatic infection. Changes in levels of immunity and spatial pat-
terns of transmission over time will also have affected age distributions of infection and dis-
ease, so the age distributions may hold important information about transmission rates in
different settings and how they have varied with time. Identification of the age groups with the
highest prevalence of asymptomatic infection (who may act as a reservoir of transmission [28–
30]) and those most at-risk of clinical VL could aid appropriate targeting of interventions to
reduce transmission and disease.
Positivity on serological tests is an indication of exposure rather than immunity, but may be
related to protective immunity. Age patterns in infection and disease are likely related to the
immunological response to L. donovani infection, many aspects of which are still unknown. In
particular, it is not known how long immunity to infection/disease lasts, the extent to which
this depends on whether the individual recovered from asymptomatic infection or from clini-
cal VL following treatment, and the degree of protection afforded [31]. Immunoglobulin G
(IgG) antibody responses to L. donovani infection are not protective against disease [32–35],
but cell-mediated immune responses are [36–40]. Thus, positivity on the leishmanin skin test
(LST), a delayed-type hypersensitivity test, does represent protective immunity. Hence, assess-
ing age patterns in sero-/LST-prevalence, sero-/LST-conversion and VL incidence may yield
insights into durations of immune responses, and variation in immunity with age and VL
endemicity.
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For example, data on seroconversion incidence by age from the TMRC study [23] suggests
that seroconversion rate may increase with age. If this is true, it has potentially important
implications for control of VL and modelling of VL transmission, as it suggests that exposure
to infected sandflies increases with age and/or that individuals living in endemic areas recon-
vert to seropositivity due to repeated bites from infected sandflies. Age-dependent exposure
has so far only be included in one transmission model of VL [3,41]. Therefore, an important
question for modelling is whether there is evidence of age-dependence in the infection rate in
the infection age-prevalence data from other studies, and whether this effect should be
included in transmission models.
In this paper, we review age-stratified data on L. donovani infection prevalence and clinical
VL incidence and fit simple catalytic models to the age-prevalence data with the aim of
improving understanding of age trends in asymptomatic and symptomatic infection. We esti-
mate sero-, PCR- and LST- conversion and reversion rates from the data and compare them to
estimates from longitudinal studies, and assess whether the conversion rates are age-depen-
dent. Catalytic models have been used in meta-analyses for a number of diseases, including
Chagas disease [11], malaria [6], varicella [42] and congenital rubella syndrome [43], to assess
changes in transmission levels and identify shifts in infection prevalence towards older ages
indicative of reduced transmission. Our goal is to provide insight into the epidemiology of VL
and help inform improvements in interventions aimed at eliminating the disease from the
ISC.
Methods
Systematic literature review
Relevant studies were identified through a systematic literature review. The search was con-
ducted using the PubMed engine via the search terms set out in S1 Text. In addition to the
PubMed search, the bibliographies of five reviews [4,27,44–46] relevant to visceral leishmania-
sis incidence/infection prevalence were analysed for references eligible for this study. Only
studies relevant to VL in the Indian sub-continent were included in the review. Any studies
referring to cutaneous leishmaniasis, muco-cutaneous leishmaniasis or conducted in another
geographical area were omitted.
The identified articles were subsequently screened based on their title and abstract, with eli-
gible articles undergoing a full-text assessment. Articles were only included if age-stratified
data was available for the incidence of clinical VL and/or prevalence of seropositivity/molecu-
lar test positivity/LST positivity, or the study-population/population-at-risk and the number
of sero-/molecular-test-/LST-positives/clinical VL cases. All numerical data from the identified
studies were doubly entered into spreadsheets and checked. The potential risk of bias in the
included studies was assessed using the Newcastle-Ottawa bias assessment scale for observa-
tional studies [47] and the Cochrane risk of bias assessment tool for intervention studies [48].
The diagnostic tests used in the identified studies were: the direct agglutination test (DAT),
recombinant K39 enzyme-linked immunosorbent assay (ELISA), rK39 rapid diagnostic test
(RDT), polymerase chain reaction (PCR), quantitative PCR (qPCR), and the leismanin skin
test (LST). Brief descriptions of the typical protocols for these tests are provided in S4 Text.
The tests measure different aspects of infection and/or associated immune responses, as sum-
marised in Table 1, so care is needed in interpreting and comparing their respective age preva-
lence patterns. DAT and rK39 ELISA are serological tests for antibodies (non-protective)
against L. donovani parasites, the rK39 RDT is a rapid test form of the ELISA designed for
diagnosis of clinical VL, PCR/qPCR is a molecular test for parasite DNA in the peripheral
blood, and LST is a delayed-type hypersensitivity test for protective T-cell-mediated immune
Systematic review of age patterns in leishmanial infection in the Indian subcontinent
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responses. Positivity on the different tests is believed to correlate to differing time since infec-
tion [23,49,50]. DAT and rK39 (ELISA and RDT) positivity represent more recent infection
than LST positivity, since antibody responses are generally much shorter lived than cell-medi-
ated immune responses [24,37,38,50,51]. The rK39 rapid test has the positive cut-off set for
clinical diagnostic purposes and does not detect the low-titre antibody responses which are
more common in asymptomatic infection. PCR positivity is also thought to represent recent
infection [52], due to the ability of PCR to detect low numbers of parasites in peripheral blood
during active infection, although longitudinal data on persistence of PCR positivity are
lacking.
Although DAT and rK39 are both antibody tests, a number of important differences make
it difficult to compare them, and to compare different DAT studies and different rK39 studies.
These include the type of antigen used (single recombinant for rK39 vs whole-parasite lysate
for DAT), how the tests are standardised against known positive and negative controls (which
differs between studies), how the DAT is read [53] and the cut-off chosen for seropositivity
(which also varies between studies). The molecular tests target different genes and are per-
formed on varying quantities of blood, affecting the diagnostic accuracy.
Case definitions
Clinical VL. For the purposes of this review, incident cases of VL were defined as those
who exhibited recognised clinical symptoms of VL (>2 weeks fever, swelling of the spleen
and/or liver, weight loss, anaemia etc. [54]) and had a positive serological status, or individuals
who were classified as ‘clinical’ or ‘symptomatic’ VL cases in their respective study (different
studies use different terms), during the study period set out in the paper.
Asymptomatic infection. An asymptomatically infected individual was defined in this
review as any individual who tested positive on a serological test for antibodies against L. dono-
vani or a molecular test for L. donovani infection, and did not exhibit clinical symptoms. This
definition covers those with active asymptomatic infection, i.e. those who harbour detectable
numbers of live parasites, and those who may go on to develop clinical disease, and also
Table 1. Characteristics of diagnostic tests used in identified studies.
Diagnostic test DAT rK39 ELISA rK39 RDT PCR/qPCR LST
Type Serological Serological Serological Molecular Skin
Antigen used Whole-parasite lysate Single recombinant K39 Single
recombinant K39
N/A (test for
parasite DNA)
Whole-parasite
Biomarker
measured
IgG antibodies� IgG antibodies� IgG antibodies� L. donovani DNA T cells
Marker of
protective
immunity
x x x N/A ✓
Test for Recent infection/ asymptomatic
infection
Recent infection/ asymptomatic infection Clinical VL Recent infection/
asymptomatic
infection
Past infection
Cut-off for
positivity
Sample dilution ratio at which
agglutination still occurs.
Variable between studies:
�1:800–1:3200
Percentile (e.g. 99th), or mean + 2 or 3
standard deviations, of distribution of optical
densities of samples from non-endemic healthy
controls. Variable between studies.
Consistent for
each
manufacturer
Variable �5mm mean
induration from
LST injection
Standardisation Variable Variable Consistent for
each
manufacturer
Variable Consistent
� IgG = Immunoglobulin G
https://doi.org/10.1371/journal.pntd.0006803.t001
Systematic review of age patterns in leishmanial infection in the Indian subcontinent
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006803 December 6, 2018 5 / 24
includes individuals who have recovered from infection who still possess antibodies against
the parasite. Since most serological studies are unable to differentiate between seropositive
individuals who have active infection and those that have dormant infection (are recovered),
and do not distinguish pre-clinical infection from genuine asymptomatic infection, we do not
differentiate these groups in this review.
Positive results by LST identify individuals with past infection, whether asymptomatic or
symptomatic, who have developed a cell-mediated immune response. In longitudinal popula-
tion-based data, positive LST results have been associated with�95% protection against subse-
quent clinical VL, and the prevalence in a population is an indication of herd immunity
[38,39]. LST positivity is considered a marker of inactive disease and appears to be a long-last-
ing response, although probably not permanent in the absence of boosting. In communities
with long-term endemic transmission, prevalence usually increases significantly with increas-
ing age, reflecting cumulative incidence over time [38,39].
In addition, due to the scarcity of cross-sectional age-stratified asymptomatic infection
prevalence data, we also include datasets with small numbers of clinical VL cases amongst the
seropositive/LST-positive individuals. We highlight which datasets this applies to, and discuss
the potential impact on the results, presenting the data on the prevalence of seropositivity/
LST-positivity by VL status from the studies where available.
Data extraction
The following data was extracted from the papers: study/institution under which the data was
collected (e.g. KALANET bed net trial, TMRC study, Indian Council of Medical Research);
start & end date of the study; country, state, district & (where available) subdistrict of the
study; number of villages; total population at risk; study population; number of excluded indi-
viduals; case definitions; type(s) of serological/diagnostic test used; age range & population of
each age-group; number of individuals who underwent diagnostic testing, number of (sero)
positive individuals; (sero)positive prevalence, number of clinical VL cases; and clinical VL
incidence. Freely available software for digitising data [55] was employed to obtain data values
from studies that did not provide numerical values for VL incidence/positive diagnostic preva-
lence, but provided relevant figures for calculation.
Statistical analysis
The age stratifications in the identified studies were used for statistical analyses (see S1 Data).
For each diagnostic test, the prevalence of infection (the proportion of the population who
were positive on the diagnostic test) in each age group in each study was plotted with exact
binomial (Clopper-Pearson) 95% confidence intervals (CI) at the mid-point of the age group,
to allow visual assessment and comparison of age trends in prevalence. Similarly, VL incidence
(as number of cases/1000 study population/year) was calculated and plotted with 95% Poisson
confidence intervals for each age group for each of the incidence studies. Odds ratios (ORs)
for the risk of being seropositive/LST-positive and risk ratios (RRs) for having VL in each age
group compared to the youngest age group were calculated with 95% CIs and 2-tailed p-values
(using the Z-test) to identify any statistically significant variation in sero-/LST-positivity and
VL incidence with age (at significance level 0.05). The chi-squared test for trend was used to
assess trends in VL incidence with age (at significance level 0.05).
For studies in which multiple diagnostic tests were performed on the same individuals, the
age-specific prevalence according to each test was plotted on the same graph for visual com-
parison and the non-parametric Friedman test was used to assess agreement in the age-specific
prevalence between the different tests, using the VassarStats online computation tool [56].
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Where possible, agreement between the different tests was also assessed by calculating Cohen’s
kappa coefficient [57] (a measure of agreement in classification between two tests, with 1 cor-
responding to perfect agreement and values�0 to no agreement), or retrieving the calculated
value from the original study.
Catalytic modelling
The infection prevalence age distribution data was modelled using a reversible catalytic model
[58] in which negative (sero-/LST-/PCR-negative) individuals become positive (sero-/LST-/
PCR-positive) at a rate λ and revert back to sero-/LST-/PCR-negativity at a rate γ (see S2 Text
for full details). We tested different versions of the model in which λ depends on age, the study
(i.e. its location and time period) and/or the diagnostic test used and γ depends on the study
and/or test (since the tests measure different immunological responses that may happen at dif-
ferent points after infection and over different timescales). We fitted the different versions of
the model to the data to estimate λ and γ using maximum likelihood estimation and compared
models using the Akaike information criterion (AIC) (see S2 Text for further details).
Results
Systematic literature review
A total of 19 age-stratified diagnostic and epidemiological studies that met the inclusion crite-
ria were identified from the systematic literature review (Fig 1). Seven of these studies con-
tained data on age-specific VL incidence (Table 2), and 13 studies contained age-stratified
infection prevalence data (Table 3) ([23] contained both types of data). A further 8 studies con-
taining age-stratified data are included in S1 Data (see S2 Data for definitions of variables in S1
Data), but are excluded from the analysis as the data is not comparable to that in the other
studies, e.g. due to differences in study design or participant inclusion criteria. The assessment
of the risk of bias in the included studies is shown in Tables 1–4 in S3 Text. Sources of potential
bias include the lack of sample size justification in all but one of the cross-sectional studies and
their failure to demonstrate comparability of non-respondents and comparability of different
outcome groups. Loss to follow up was a potential source of bias in most cohort studies. We
were unable to assess the risk of publication bias due to the small number of studies that met
the inclusion criteria.
Age trends in VL incidence
The age-specific VL incidence curves for the studies in Table 2 are shown in Fig 2. The large
variation in measured incidence between different studies is immediately apparent, and not
unexpected given the differences in incidence between different geographical locations and
different time periods. The highest average VL incidence, 13.2 cases/1000 people/year, was
observed in the study of Bern et al [25], in Fulbaria upazila, Mymensingh district, Bangladesh,
between 1999 and 2004.
There is a general pattern of decreasing VL incidence with increasing age beyond 20 years
(Fig 2), although the trend is not significant for all studies (see p-values for chi-squared trend
test in S3 Data). The exception (Barnett et al [59]) was conducted in outbreak villages in low-
endemicity areas in Uttar Pradesh, India. Most of the studies for which incidence data for 0-
10-year-olds is available show lower VL incidence among young children (0-5-year-olds) than
older children and young adults (5-20-year-olds), with a peak in incidence in the 5-20yr age
group (see RRs in S3 Data).
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Age trends in infection prevalence
Fig 3 shows age-prevalence curves for L. donovani infection from the studies in Table 3, with
results separated by test. For studies in which multiple tests were performed on the population
[23,24,68,70] the data are plotted together in Fig 4 to allow comparison of age-specific preva-
lence according to the different tests.
DAT. All studies that utilised DAT show a general increase in prevalence of DAT positiv-
ity with age up to 30-40yrs (Fig 3A). Above age 40, some studies show a continuing increase in
seroprevalence with age [23,67,69] (see OR tables in S3 Data), while other studies suggest a
decrease (albeit non-statistically significant) in DAT prevalence [66,68,70].
Since the DAT cut-off represents the dilution at which the sample is considered positive if it
still reacts with the antigen, it might be expected that studies that used a lower DAT cut-off
would generally report higher seroprevalences than those using a higher (more restrictive) cut-
off. However, taking into account the variation in study settings, there is no clear trend in sero-
prevalence with DAT cut-off (Fig 3A), so differences in cut-off do not explain the variation in
Fig 1. PRISMA flow diagram of the inclusion and exclusion of studies identified in the literature search.
https://doi.org/10.1371/journal.pntd.0006803.g001
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Table 2. Summary of identified age-stratified clinical VL incidence studies.
Study Location Date Study
Population
Total VL
Cases
Clinical VL Incidence (per 1000
people/yr)
Serological Test
From To rK39
RDT
rK39
ELISA
DAT
Barnett et al, 2005 [59] Uttar Pradesh,
India
1999 2004 2203 43 6.5 ✓
Bern et al, 2005 [25] Bangladesh 01/
1999
06/
2004
2507� 182� 13.20 ✓ ✓
Ferdousi et al, 2010 [60] Bangladesh 08/
2006
08/
2008
6955 248 12.23 ✓
Hasker et al, 2012 [61] Bihar, India 09/
2008
10/
2010
81210 207 0.73 ✓
Hasker et al, 2013 [23] Bihar, India 03/
2007
12/
2009
19886 115 3.17 ✓ ✓
Picado et al, 2014 [62] India + Nepal 11/
2006
05/
2009
17610 95 2.16 ✓ ✓
Singh et al, 2010a [63]�� Bihar, India 01/
2006
12/
2006
31324 177 5.7
� Figures taken from Chapman et al (2015) [2].
�� Information on serological testing performed for Singh et al, 2010a not available
https://doi.org/10.1371/journal.pntd.0006803.t002
Table 3. Summary of identified age-stratified infection prevalence studies.
Study Location Year Total tested Total positive Prevalence (%) Diagnostic Test
rK39 RDT rK39 ELISA DAT LST PCR/qPCR
Bern et al, 2006 [38] Bangladesh 2002 1532 530 34.6 ✓
Bern et al, 2007 [24]� Bangladesh 2002 1599 298 18.6 ✓
2003 1827 274 15.0 ✓
2004 1832 245 13.4 ✓
Hasker et al, 2013 [23]�� Bihar, India 2009 12605 ✓ ✓
Kaushal et al, 2017 [64] West Bengal, India 2014 246 55 22.4 ✓
Koirala et al, 2004 [65] Nepal 1996 1083 66 6.1 ✓
Nandy et al, 1987 [37] West Bengal, India 125 24 19.2 ✓
Ostyn et al, 2015 [66] Nepal 2014 418 40 9.6 ✓
Patil et al, 2013 [49]�� West Bengal, India 2000–2001 44.4 ✓
44��� ✓
Rijal et al, 2010 [67] Nepal 2006 5397 489 9.1 ✓
Schenkel et al, 2006 [68]�� Nepal 2003 365 28 7.5 ✓
373 48 11.2 ✓
Singh et al, 2010b [69] Bihar, India 2006 8051 1490 18.5 ✓
Topno et al, 2010 [70]�� Bihar, India 355 39 11.0 ✓
28 7.9 ✓
24 6.8 ✓
Yangzom et al, 2012 [71] Bhutan 396 43 10.9 ✓
� Age-stratified data previously unpublished.
�� Denotes study where age stratified data was provided for each serological test.
��� DAT data not included in analysis since data deemed unreliable due to low cut-off used
https://doi.org/10.1371/journal.pntd.0006803.t003
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seroprevalence between studies. Prevalence curves from Topno et al [70] (cut-off 1:800), Rijal
et al [67], Hasker et al [23] (both cut-off 1:1600) and Koirala et al [65] (cut-off 1:2000) follow
the expected trend, but those for the other studies do not. For example, the seroprevalence in
the Schenkel et al [68] study (cut-off 1:3200), is higher than in the Hasker et al (cut-off 1:1600)
and Koirala et al (cut-off 1:2000) studies up to age 50, and the seroprevalence in the Singh et al
[69] study (cut-off 1:1600) is higher across all age groups than in all the other studies.
rK39 ELISA and RDT. Relatively few studies have examined age patterns in rK39 positiv-
ity, either by ELISA or the RDT. Those that have suggest rK39 seroprevalence increases up to
at least age 25 (Fig 3B), with data from the TMRC study showing an increasing trend in rK39
ELISA positivity with age up to 70 (p<0.001 for chi-squared test for trend [23]). Differences in
seroprevalence by rK39 ELISA between age groups in longitudinal data from the study of Bern
et al [24] in Bangladesh from 2002 to 2004 were not statistically significant, apart from in the
final year of the study where seroprevalence was higher amongst 10-39-year-olds than 3-
9-year-olds (see S3 Data). The data also show that rK39 positivity decreased across all ages as
the epidemic waned in the study population in 2003 and 2004 [51], towards a distribution
Table 4. Infection prevalence by different diagnostics and VL status.
Study Location VL status n No, DAT/rK39 ELISA
positive
No. LST
positive
No. rK39 RDT
positive
No. PCR/qPCR
positive
Bern et al, 2007 [24]� Bangladesh Past VL 81 64 (79%) 51 (63%)
Current VL 14 14 (100%) 1 (7%)
Subsequent VL 39 14 (36%) 1 (3%)
No VL 1340 181 (14%) 452 (34%)
Koirala et al, 2004 [65] Bihar, India Any 1083 66�� (6.1%)
Nandy et al, 1987 [37] West Bengal,
India
Past VL 25 20 (80%)
No h/o VL 125 24 (19%)
Ostyn et al, 2015 [66] Nepal Past VL 23 22 (96%)
No VL 418 40 (9.6%)
Rijal et al, 2010 [67] Nepal VL�2yrs
previously
93 90 (97%)
VL>2yrs
previously
182 173 (95%)
No h/o VL 5120 226 (4.4%)
Schenkel et al, 2006
[68]
Nepal Past VL 19 18 (95%) 4 (21%)
No h/o VL 354 10 (2.8%) 44 (12%)
Singh et al, 2010 [69] Bihar, India VL�2yrs
previously
269 250 (93%)
VL>2yrs
previously
358 304 (85%)
No h/o VL 7418 936 (13%)
Topno et al, 2010
[70]���
Bihar, India Any 355 39���� (11%) 24† (7%) 28‡ (8%)
h/o = history of
� 2002 data
�� Out of 66 DAT+: 22 current VL, 23 treated for VL�1 year previously, 21 asymptomatic, of which 9 developed VL in�6mos
��� Out of 50 DAT+/rK39 RDT+/PCR+: 10 symptomatic (current VL / VL�6mos previously), 40 asymptomatic, 2 of which had h/o VL�6mos previously. Out of 38
asymptomatic without h/o VL, 7 developed VL in�6mos.
���� Out of 39 DAT+: 7 current VL, 2 with h/o VL�6mos previously
† Out of 24 RDT+: 6 current VL, 2 with h/o VL�6mos previously
‡ Out of 28 PCR+: 7 current VL, 1 with h/o VL�6mos previously
https://doi.org/10.1371/journal.pntd.0006803.t004
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similar in shape to the cumulative VL incidence age distribution (Fig 2). The age-prevalence
patterns in the TMRC and Bangladesh studies are not comparable due to differences in test
standardisation and the cut-off used for asymptomatic seropositivity [23,51,72]. Similarly
rK39 ELISA and rK39 RDT results are difficult to compare since positivity on the rK39 RDT
generally corresponds to a higher rK39 antibody titre than is typically used as the rK39 ELISA
seropositivity cut-off, particularly if the RDT is performed on whole blood rather than serum
[73].
PCR/qPCR. Age-stratified data on prevalence of PCR positivity was available from only
two studies [64,70] (Fig 3C). In the Topno et al study there was a decrease in the proportion
PCR positive with age, although the trend was not significant, while in the Kaushal et al study
the proportion qPCR positive was highest in the 19–44 age group (OR 2.87 (95% CI 1.28–6.43,
p = 0.010) compared to the 0–18 age group). We note that PCR prevalence data for 668 indi-
viduals in the KALANET trial in India and Nepal also showed no consistent age pattern, with
a slightly increasing prevalence with age in India and decreasing prevalence with age in Nepal
[41].
Agreement between different tests. Despite the apparent agreement between the overall
prevalence of seropositivity in each age group according to DAT and rK39 ELISA in the
TMRC study (Fig 4B), agreement between the two tests was actually poor (Cohen’s kappa, κ =
0.30), i.e. different individuals were seropositive according to the two tests. Poor agreement
was also observed between rK39 RDT and qPCR results in the Kaushal et al [64] study (κ =
0.089). This may be due to a number of factors–differences in the sensitivities and specificities
of the tests, differences in what the tests measure (as described above), and how well the tests
were standardised and performed. The non-parametric Friedman test used to compare age-
specific prevalence according to DAT, rK39 RDT and PCR for the Topno et al [70] (Fig 4D)
Fig 2. Age-specific visceral leishmaniasis incidence (cases per 1000 individuals per year) in different studies in the
Indian subcontinent.
https://doi.org/10.1371/journal.pntd.0006803.g002
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study showed no significant difference in age-specific prevalence between the three tests
(p = 0.1969). Furthermore, Cohen’s kappa coefficients calculated for each pair of tests ranged
from 0.56 (for DAT vs PCR) to 0.64 (for DAT vs rK39 RDT), indicating moderate to substan-
tial pairwise agreement between the tests at individual-level [74] in this study.
LST. Age-prevalence patterns were not consistent across the five identified LST studies,
and overall LST-positive prevalence varied considerably (from 10.9% to 44.4%) (Fig 3D). How-
ever, the studies of Bern et al [38] and Yangzom et al [71] showed clear increasing trends in
the proportion positive with age, from 17% in the 3–9 age group up to 59% in the 60+ age
Fig 3. Age-prevalence distributions of positivity on different diagnostic tests for Leishmania donovani infection in the Indian subcontinent. (A) Seropositivity by
Direct Agglutination Test (DAT) (numbers in parentheses denote cut-off for positivity), (B) seropositivity by rK39 Enzyme Linked Immunosorbent Assay (ELISA) or
Rapid Diagnostic Test (RDT), (C) Polymerase Chain Reaction (PCR)/quantitative PCR (qPCR) positivity for parasite DNA, (D) LST positivity. All the prevalence
studies include individuals with active or dormant asymptomatic infection, and some include a small number of active VL cases or exclude past VL cases. The year in
which the survey was performed is shown in square brackets.� Prevalence includes a small number of active clinical VL cases.�� Past VL cases excluded from
prevalence.��� Data includes two individuals who were rK39 RDT+ but qPCR-.
https://doi.org/10.1371/journal.pntd.0006803.g003
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group in the former, and from 6.5% in the 2–15 age group to 15% in over-45s in the latter,
despite being performed in settings with very different endemicities.
The highest overall LST-positive prevalence (44%) was in the study of Patil et al [49] in
West Bengal. In this study, a higher proportion of young and middle-aged adults (aged 11 to
40) than 0-10-year-olds and over-40s were LST positive. DAT data from the same individuals
showed higher seroprevalence among 11-40-year-olds (48%) than 1-10-yr-olds and over-40s
(40% and 41% respectively), suggesting higher rates of relatively recent infection and conse-
quent LST conversion in this age group.
Fig 4. Comparison of age-prevalence distributions of positivity on different diagnostic tests for L. donovani infection in studies with multiple diagnostic tests.
(A) Bern et al [24,38]: prevalences of rK39 ELISA and LST positivity, (B) Hasker et al [23]: rK39 ELISA and DAT seroprevalences (C) Schenkel et al [68]: DAT
seroprevalence and LST positivity, (D) Topno et al [70]: DAT, rK39 RDT and PCR test positivities. � Prevalence includes a small number of active clinical VL cases.��
Past VL cases excluded from prevalence.
https://doi.org/10.1371/journal.pntd.0006803.g004
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Similarly to Bern et al’s study, the study of Nandy et al [37] in an endemic village near West
Bengal showed a general increase in prevalence of LST positivity with age, albeit with a higher
prevalence among 0-10-year-olds than 11-20-year-olds.
In contrast to the other studies, the prevalence of LST positivity in the Schenkel et al [68]
study in southeastern Nepal was relatively low across all age groups (0–18%) and showed no
pattern with age. It is possible that a smaller proportion of this population was exposed to the
parasite and developed cell-mediated immunity due to the lower endemicity of the study loca-
tion, but issues with the sensitivity and potency of the L. infantum antigen used [38] likely con-
tributed to the low LST prevalence observed, especially given the low proportion of LST
positivity in past VL cases (21% compared to 63% and 80% in the Bern and Nandy studies).
These data suggest that standardisation of leishmanin is critical, and was not uniform, across
these studies.
Effect of VL status on diagnostic results. Since the infection prevalence studies shown in
Fig 3 differ in terms of whether they include/exclude active/past VL cases, and this may affect
the age-prevalence distribution, we also recorded data on prevalence of sero-/LST-positivity
by VL status from these studies when available (see Table 4). The high prevalences of DAT/
rK39 ELISA positivity amongst past VL cases shown in Table 4 reflect the persistence of high
antibody levels in treated VL patients [23,75], and are likely to have affected the age-prevalence
distributions to some extent since they are much higher than the prevalences in individuals
with no history of VL. Likewise, prevalence of LST positivity was much higher in past VL cases
than in individuals without previous VL, suggesting that inclusion of past VL cases will have
affected the age-prevalence pattern of LST positivity. However, the number of active VL cases
observed in any of the cross-sectional studies was small relative to the number of sero-/LST-
positive individuals, so their inclusion is unlikely to have significantly biased the age-preva-
lence distributions.
Catalytic modelling. The best-fitting model based on AIC is the model in which the con-
version and reversion rates, λ and γ, are independent of age but study-specific. This has a
lower AIC than the model with age-dependent and study-specific conversion rates and study-
specific reversion rates (ΔAIC = 6.5), which is the next best-fitting model (and has a higher
likelihood). The models in which the conversion and/or reversion rates are test-specific or the
same across all studies have considerably higher AICs (see S2 Text for full results). The (λ,γ)
estimates for the age-independent and age-dependent models with study-specific conversion
and reversion rates are shown in Fig 5, along with estimates of seroconversion and serorever-
sion rates from studies in which there were repeated measurements [23,24,50]. Whilst there
appears to be some clustering in the estimated rates by test type in the age-independent model
(Fig 5A)–e.g. the LST reversion rates are generally lower than the DAT reversion rates, which
are generally lower than the rK39 reversion rates–this accounts for less of the variation in the
estimates than the data source study. The ranges of the estimated λ and γ values for each test
are large, e.g. [0.0037,0.026]yr−1 and [0.021,0.18]yr−1 respectively for DAT, and the median
values for DAT, λ = 0.0091yr−1 and γ = 0.077yr−1, correspond to 20% of individuals having
been infected by age 24 and an average duration of positivity of 13yrs. Many of the estimated
conversion rates and nearly all of the estimated reversion rates are lower than the estimates
from the longitudinal studies, e.g. for the Hasker et al 2013 study the estimated rates for DAT
are λ = 0.0037yr−1 and γ = 0.021yr−1, while the longitudinal estimates are λ = 0.026yr−1 and γ =
0.46yr−1. Two possible explanations for this are that the infection rate does actually increase
with age, and/or that the infection rate is highly heterogeneous, i.e. transmission is localised
around infectious individuals in such a way that only a certain proportion of the population
(corresponding to the maximum in the age-prevalence curve) ever becomes infected. Account-
ing for this age-dependence and/or spatial heterogeneity would lead to higher estimates for λ
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and γ, since if λ increases with age a higher value of γ is required to achieve the same preva-
lence, and if transmission decreases with distance from infected individuals a higher average
value of λ is required to reach the same prevalence (and therefore a higher value of γ to obtain
the same age-prevalence distribution). The estimated rates from the age-dependent model
are indeed much closer to the longitudinal estimates, e.g. for the Hasker et al 2013 study
λ = 0.022yr−1 at the median age (19yrs) and γ = 0.37yr−1 (corresponding to an average duration
of positivity of 2.7yrs), which supports the theory that λ is age-dependent. However, it is not
possible to assess the impact of spatial heterogeneity in transmission from the available data.
Discussion
The systematic review and meta-analysis of the age-related prevalence and incidence of L.
donovani infection and disease in the ISC in this paper has found weak evidence for age-
related infection rates. However, there is considerable variation in the data that might be mask-
ing such an effect, so no definitive conclusion can be drawn. Nevertheless, it seems likely that
even if there is an age-effect in exposure and infection, it is less significant than the strong tem-
poral and spatial dependence of VL transmission risk [18].
There is considerable variation in observed L. donovani infection prevalence and disease
incidence by geographical location, endemicity level and time period. Broadly speaking, stud-
ies performed more recently have found lower VL incidence rates due to the significant overall
decline in VL incidence in India, Bangladesh and Nepal [76] over the past decade, and those
performed in India and Bangladesh have observed higher VL incidence and infection preva-
lence than those in Nepal (see Tables 2 and 3, Table S1 in [50], and Table J S1 text in [27]).
Despite this variation, there is a relatively consistent pattern of lower seroprevalence (by
DAT and rK39) and VL incidence among young children (0-5-year-olds) than older children
(5-20-year-olds). Various theories have been put forward to explain the lower reported VL
incidence among young children [77], including lower exposure to bites from infected sand-
flies in young children, possibly based on different sleeping behaviours.
Fig 5. Estimated conversion and reversion rates, λ and γ, from (A) age-independent (λ = b0 = constant) and (B) age-dependent (λ = b0 + b1 × age) reversible
catalytic models for the age-prevalence distributions of infection for the different studies in Table 3. Crosses show the maximum likelihood estimates for (λ,γ) for
each study, dots (λ,γ) estimates from longitudinal studies [23,24,50], and lines their 95% confidence intervals. λ estimates in (B) are at age 20yrs (i.e. λ = b0 + 20b1).
https://doi.org/10.1371/journal.pntd.0006803.g005
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Reported age patterns in seroprevalence are less consistent over age 20yrs and vary by sero-
logical test. Some DAT studies suggest continually increasing seroprevalence with age, but
other DAT studies and rK39 ELISA surveys suggest lower or similar seroprevalence for over-
40s as for 20-40-year-olds. One potential explanation is differences in boosting of antibody lev-
els in asymptomatically infected individuals from repeated exposure to the parasite from
infected sandflies [23]. This theory is supported by the increase in both the DAT seropreva-
lence and DAT/rK39 seroconversion rate with age observed in highly endemic villages in
Muzaffarpur, Bihar, in the TMRC study [23].
Prevalence of LST positivity appears to generally increase with age in highly endemic set-
tings, likely due to an increase in cumulative exposure to the parasite with age and the poten-
tially long duration of cell-mediated immunity. Data from LST surveys in Ethiopia conducted
one year apart showed 5% reversion from positive to negative LST [78] suggesting that
repeated exposure to infected sandflies may be required to maintain LST positivity; this may
help explain some of the differences in age patterns between the studies. Another cause of dif-
ferences may be the leishmanin antigen (L. major or L. infantum), and its sensitivity and
potency [38]. Although LST is a potentially valuable tool for assessing transmission intensity
and immune status in communities [37,78], new sources of well-standardised leishmanin anti-
gen are required, preferably produced under internationally recognized Good Manufacturing
Practices (GMP). The only antigen currently available (L. major MRHO/IR/75/ER antigen
from the Pasteur Institute in Iran) gave unreliable results when it was trialled for use in the
KALANET study and was abandoned [79].
Nearly all of the reviewed VL incidence studies showed a peak in incidence between the
ages of 5 and 20, with lower incidence in adults over 40. Together with the apparent general
increase in seroprevalence and LST positivity with age, this suggests that immunity to VL
increases with age. However, VL incidence varies in long-term cycles at district and state level
in the ISC with peaks approximately 15 years apart [80–82], so age patterns of infection preva-
lence and cumulative VL incidence will vary according to the point in these epidemic cycles at
which the studies were conducted. Likewise, within these longer term cycles VL tends to occur
in localised epidemics, affecting villages for a few years before moving to neighbouring villages,
so the timing and location of studies relative to these micro-epidemics will have an impact on
age patterns [50,83]. There is also seasonality in VL incidence due to seasonality in sandfly
abundance [3,77,84] and evidence of seasonal variation in seroprevalence [85]. Thus, the time
of year at which the cross-sectional serological surveys were performed and period over which
the cumulative VL incidence was recorded may have also affected the observed age patterns.
Accurate comparison of age trends in asymptomatic infection and VL incidence between
studies is hindered by a lack of consistency in study design, data presentation, and standardisa-
tion of diagnostic test protocols and cut-offs for positivity. Diagnostic studies vary regarding
inclusion/exclusion of active/past VL cases, despite the fact that this can affect the age pattern
of infection (Table 4 and S1 Data). Many serological and epidemiological studies do not report
the age distribution of seropositivity or VL incidence, or for the latter only report the age dis-
tribution of cases and not that of the whole study population, even though this data is routinely
gathered and potentially epidemiologically useful. Thus, there is relatively little published data
with which to assess age patterns in infection prevalence and disease incidence and how they
relate to each other. More regular and consistent collection and presentation of age prevalence
and incidence data would greatly assist in identification and comparison of age trends in
asymptomatic infection and clinical VL.
Given issues of different test standardisation between studies, potential difficulties with
standardising test protocols across studies in the future, and possible repeated sero- and LST-
conversion from re-exposure, data from longitudinal studies on sero- and LST- conversion
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and reversion may be more useful than data from cross-sectional surveys at present. Compara-
tively few longitudinal studies of sero- or LST- conversion and progression to VL associated
with different diagnostic results have been conducted. Those that have been performed suggest
that agreement between different diagnostics in terms of predicting risk of progression to VL
is poor [26]. What is known is that high-titre DAT/rK39 ELISA seropositivity and seroconver-
sion correlate with progression to VL [26,51], and LST positivity means a very low risk of sub-
sequent VL in the absence of immunosuppression [38,78,86].
Although we found no statistically significant differences in age-specific infection preva-
lence according to different diagnostics tested on the same study population, agreement
between different diagnostics in these studies was generally poor, as found in other studies
[52,87–89]. A number of authors have suggested that these discrepancies are due to differences
in kinetics between bio-markers and the sensitivities of different diagnostics, such that differ-
ent diagnostics become positive/negative at different points in the course of infection and to
varying degrees dependent on whether the individual is asymptomatic or pre-symptomatic
[23,49,50,52]. Mathematical modelling studies have used combinations of different diagnostic
test results to try to stage infection [41,51,90]. However, the true picture is likely more compli-
cated, due to individual-level heterogeneity in parasite loads and immune responses, potential
boosting of antibody levels in asymptomatically infected individuals from re-exposure and
intermittent proliferation of parasites contained in safe target cells [23], and the unknown tem-
poral dynamics of different infection markers in asymptomatic infection. Various studies have
investigated the temporal dynamics of different biomarkers in clinical VL [23,36,75,91–93],
mostly from treatment onwards, but equivalent studies for asymptomatic infection are lacking
[50], no doubt in part due to the difficulty of defining asymptomatic infection.
The parameter estimates obtained from the catalytic model reflect the significant variation
in infection and reversion rates by study location and time period. There is more variation
between studies than between tests. The catalytic models with an age-independent conversion
rate give underestimates of the conversion and reversion rates based on direct estimates from
longitudinal data. Models with an increase in the conversion rate with age provide estimates
closer to the longitudinal estimates, suggesting that age-dependent exposure or age-dependent
seroconversion upon infection are possible explanations for the discrepancy. However, evi-
dence that the conversion rate increases with age is relatively limited, and time-dependent
changes will induce age-dependent patterns for long duration markers. For example, a sero-
conversion rate that increases linearly with age could also be the result of a linear reduction in
transmission intensity with time. The trend in the Hasker et al study [23] is clear, but overall
the age-dependent catalytic models do not fit the data better than the age-independent models,
and other studies do not show the same trend in seroconversion rate with age [24,62]. Never-
theless, the lack of strong evidence that the infection rate is age-independent suggests that age-
dependence should be included in models of VL transmission dynamics in the ISC. If exposure
is not age-dependent, a natural question is why there is an age pattern in VL incidence. The
simplest explanation is that risk of disease given infection increases with age up to 15–20 years
and then decreases. Another possible explanation for the estimated conversion and reversion
rates being lower than expected is that infection and immunity are highly localised, and so
only a certain proportion of the study population is actually at risk of infection, rather than the
whole study population being equally at risk as assumed in the analysis.
Due to a lack of available disaggregated data, we have not explored the role of possible con-
founders for age patterns in seroprevalence and VL incidence, such as sex and spatial proxim-
ity to VL cases and infected individuals. Various studies have observed higher VL incidence in
males than females [62,77,81,94,95] and some have observed higher sero-prevalence/conver-
sion in males [62,67,69], both of which may be caused by socio-behavioural and/or biological
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factors [67,69,95–99]. The differences between sexes appear to vary with age [67,69,77], so may
affect observed age patterns. Proximity to VL cases and/or infected individuals is known to be
a risk factor for infection and disease, with numerous studies showing higher rates of seroposi-
tivity, seroconversion, VL, and LST positivity in individuals who share a house with or live
near a previous VL case or seropositive individuals [24,25,37,62,67,87,88]. Although we
excluded any studies that focused on close contacts of VL cases, differences in spatial clustering
of transmission in different settings may have affected the observed age patterns in seropreva-
lence and VL incidence. Due to the absence of published age-stratified data on other poten-
tially promising diagnostics, such as urinary antigen tests, sandfly saliva antibody tests, and
interferon gamma release assays [4,100,101], we were only able to review age patterns for the
most widely used diagnostics.
Conclusion
The main conclusion that can be drawn from this review is that age patterns of L. donovani
infection measured using current serological tests appear to be too variable across different set-
tings and endemicity levels to be used to monitor levels of ongoing transmission post elimina-
tion. The extent to which this variability is due to genuine variation in the age-prevalence
distribution with location and time, to properties of the tests, and/or to inconsistent test stan-
dardisation is unclear. However, the fact that significant age trends have only been observed in
large studies suggests that very large sample sizes would be needed to reliably detect changes in
transmission levels based on age patterns. Further longitudinal studies are required to improve
understanding of the dynamics of serological responses and to determine whether serological
tests can be used as a surveillance tool to monitor transmission. If such studies can demon-
strate that well-standardised serological testing provides a reliable indicator of transmission,
cross-sectional serological surveys may still prove to be a useful tool for achieving and sustain-
ing elimination of VL as a public health problem in the ISC.
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